ANLISISDEUNESTUDIODE UTILIZACIN DE MEDICAMENTOS.UNIVERSIDAD NACIONAL DE COLOMBIA FACULTAD DE MEDICINAFARMACOLOGA2015GERMAN EDUARDO FONSECA MEDINAFABIN CAMILO GALEANO BUITRAGOANDREA NATALLY GARZN HERNNDEZELEANNY DEL MAR GUTIRREZ PERALTAOSCAR EDUARDO GUZMN MENDOZAERIN FELIPE HERNANDEZ DURANESTUDIO DE UTILIZACIN DE MEDICAMENTOS!OURNAL OF CRITICAL CARE P"#$$%&'()*"+,$-./()*"020112,$132145")%/($6 ,$)-."*$+)$+"01126%7(+,$&*+",$89+$:-#*(#,$6( )(*$7"+;( Critical Care and Intensive Care Medicine.E#/%7-)(3 C6;&-)( 5 S(6%, P@7-)(. 0EAUATDUR 22S$#7"# .9. R$#%6*(,"#5. A/6-)(&,$$#*($*(/(?&(6)"."& ,$ 6( #$)+$)->& M)-,( $&*+$ %& 40P44Q /"+ 29 G"+(#.2.2 !USTIFICACIN FISIOPATOLGICAI INHIBIDORES DE LA BOMBA DE PROTONES 0IBP21ars 2lbe, Enar 3arlsson and Per 1indberg. A proton-pump inhibitor e4pedition. the case histories of omepra"ole and esomepra"ole. Nature 5eviews. #rug #iscovery. )*-$6 (7+. -$)--$8.2.2 !USTIFICACIN FISIOPATOLGICAI ANTAGONISTAS DEL RECEPTOR H2 DE HISTAMINA 0ARH221ars 2lbe, Enar 3arlsson and Per 1indberg. A proton-pump inhibitor e4pedition. the case histories of omepra"ole and esomepra"ole. Nature 5eviews. #rug #iscovery. )*-$6 (7+. -$)--$8.9incen"o Savarino, :rancesco #i !ario, 3armelo Scarpignato. Proton pump inhibitors in;25#.Anoverviewoftheirpharmacology,efficacyandsafety.Pharmacological Research 59 (2009) 15!152.2 !USTIFICACIN FISIOPATOLGICAI ANTAGONISTAS DEL RECEPTOR H2 DE HISTAMINA 0ARH22S%/+-.$&6(#$)+$)->&,$M)-,")6"+G;,+-)"/+",%)-,"/"+ 6(#)C6%6(#/(+-$*(6$#,$6$#*>.(7"3(67-)" .M# /+$#)+-*" /(+( 6( P+"?6(H-# ,$ J6)$+( /"+ E#*+C# 0SUP22. E:(6%(+ 6(# *$&,$&)-(# $& 6( %*-6-L()->& ,$ SUPS 5 1. R$/"+*(+ $6 )"++$)*" %#" ,$ /+"?6(H-# #$7@& $#*+(*-?)()->& /"+ +-$#7" ,$ #(&7+(,".M+T&,&*.Ti-. de est/di.0.M%6*-)C&*+-)".P+"#/$)*-:".P+$:(6$&)-( /%&*%(6..O& /()-$&*$# (,%6*"# /"+ 29 G"+(#.1.1 DISEYO METODOLGICOP.1laci2nI 589 /()-$&*$# ,$ 58 UCI ,$ 2T G"#/-*(6$# ,$ E.E.U.U. 5 C(&(,M.N" %*-6-L(+"& )"$&*-.-$&*" -&'"+.(,".Criteri.s de e3cl/si2n0 M$&"+ ,$ 18 (Z"#H$."++(7-( (7%,( ,$ :;(# ,-7$#*-:(# (6*(# $6 ,;( ,$6 -&7+$#"3 "I&'"+.()->& -%?)-$&*$ $& 6"# +$7-#*+"# .C,-)"#. 1.1 DISEYO METODOLGICO4a tera-ia anti5cida se c.nsidera a-r.-iada en0P()-$&*$# ,$ (6*" +-$#7" ,$ #(&7+(," )"& (,.-&-#*+()->& -&*+(G"#/-*(6(+-( ,$ *$+(/-( #%/+$#"+( ,$ M)-,".P()-$&*$# )"& *$+(/-( #%/+$#"+( ,$ M)-," (&*$# ,$ -&7+$#" ( G"#/-*(63 N%$ )"&*-&@(& )"& 6( .-#.( .$,-)()->&. P()-$&*$# ,$ &3 /(+( :$+ #% -,"&$-,(,.L"# EUM /%$,$& 66$:(+#$ ( )(& ,$ 6"# ,(*"# A&M6-#-# ,$ 6"# .-#."#.C(,( %&" -&*$&*( -,$&*-?)(+ /"#-& ,$ /"+ 6" .$&"# 2 +$:-#"+$#.R$:-#"+ 1I 4[10R$:-#"+ 2I 8[109. RESULTADOS< E6 54Q ,$ 6(# -*-*%)-"&$# )%$&*(& )"& 7%;(# ,$ .(&$F".< E& $#*(#3 $6 'M+.()" ,$ /+-.$+( $6$))->& $#I < H2RAUB23Q < PPIUBQ < S-& /+$'$+$&)-(U12Q9. RESULTADOS< C"(7%6"/(*;(U2B /()-$&*$# 0935Q2< E&'$+.$,(,$# (#")-(,(# )"& -%?)-$&)-( +$#/-+(*"+-(U 151 /()-$&*$# 02B32Q2< P()-$&*$# )"& *$+(/-( (&*-M)-,( /+$:-( ( G"#/-*(6-L()->&I 229 018Q2< H2RAU 14 01T.9Q2< PPIU181 080.8Q2< A.& (/+"/-(,( ,$ SUPI I&)-,$&)-( ,$ SUP (/+"/-(,( $& UCI#IC"& 7%;( ,$ .(&$F"I TTQ 0281[1BB2 S-& 7%;( ,$ .(&$F"I 81Q 01TT[21829. RESULTADOSP+$,-)*"+$# .M# '%$+*$# ,$ SUP -&(/+"/-(,(IT$+(/-( ?7-)(#5R$())-"&$# A,:$+#(#M$,-)(.$&*"#(#,$6"#(&*-%6)$+"#"#3#-& $.&S$#7" ,$ (#-7&()->&S$#7" ,$ (#-7&()->&S$#7" ,$ #$7%-.-$&*"S$#7" ,$ #$7%-.-$&*"S$#7" ,$ .$,-)->&S$#7" ,$ .$,-)->&S$#7" ,$ (&M6-#-#S$#7" ,$ (&M6-#-#S$#7" ,$ /%&S$#7" ,$ /%&S$#7" ,$ /+$#$&*()->&S$#7" ,$ /+$#$&*()->&SESGO DE SELECCIN E& $#*$ $#*%,-" ,$ /+$:(6$&)-( #$ #$6$))-"&(+"& /()-$&*$# N%$ '%$+"& (,.-*-,"# ( %&-,(, ,$ )%-,(,"# -&*$-:"# $& G"#/-*(6$# ,$ E#*(,"# U&-,"# 5 C(&(,M.S$ $H)6%5$+"&IP()-$&*$# .$&"+$# ,$ 18 (Z"#P()-$&*$# N%$ #$ /+$#$&*(+"& )"& #(&7+(," (7%," ,$ :;(# ,-7$#*-:(# (6*(#.S- 6( -&'"+.()->& ,$ 6( G-#*"+-( )6;&-)( #$ F%L7(& *(.& ,-(#*>6-)( c100 ..H7 (@& )"& $6 (,$)%(," *+(*(.-$&*" )"& \%-,"# $& +$#%)-*()->& 5 #-7&"# ,$ G-/"/$+'%#->&2.1. P()-$&*$# N%$ &" )%./6-$+"& )"& 6"# )+-*$+-"# ,$ 6( ,$?&-)->& ,$ (6*" +-$#7" #$ ,$?&-$+"& )"." ,$ &. U#" /(#(," ,$ :$&*-6()->& .$)M&-)( -&:(#-:( 5 &" -&:(#-:( U#" ,$ AINES U#" ,$ 'M+.()"# $#*$+"-,$# #-#*C.-)"# R$)$/*"+ ,$ *+('%#->& #(&7%;&$( L$#->& ,$ .$,%6( $#/-&(6 T$+(/-( :(#"/+$#"+( U#" ,$ a(+'(+-&( T+(%.( .@6*-/6$ H$/(*$)*".;( /(+)-(6 T$+(/-( ?+7(&"# " *$F-," A&*$)$,$&*$ ,$ #(&7+(," 7(#*+"-&*$#*-&(6.SESGO DE ASIGNACIN4.s criteri.s >/e -er9iten @acer la estrati7caci2n -.r 6r/-.s de ries6. en el est/di. s.n -.c. clar.s % n. .1edecen al /s. de escalas dia6n2sticas c.n ace-taci2n internaci.nal.4a 6ran cantidad de criteri.s eval/ad.s >/e @acen c.rrect. el /s. de tera-ia -r.7l5ctica a/9enta la valide= interna del est/di..SESGO DE MEDICINN" #$ G()$ .M# -&*$+:$&)->& N%$ $6 "& ,$ ,(*"# %#(," '%$ %& '"+.(*" a$< $#*(&,(+-L(," ,$ +$/"+*$ ,$ )(#"# /(+( *","# 6"# G"#/-*(6$#3$6 )%(6 '%$ ,-#$Z(," /"+ $6 7+%/" ,$ -&:$#*-7()->& 5 /+"